{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Winslow U"],"funding":["Novo Nordisk Fonden"],"pagination":["e0288756"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10355384"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(7)"],"pubmed_abstract":["Objective
Hypokalemia is associated with increased risk of arrhythmias and it is recommended to monitor plasma potassium (p-K) regularly in at-risk patients with cardiovascular diseases. It is poorly understood if administration of potassium supplements and mineralocorticoid receptor antagonists (MRA) aimed at increasing p-K also increases intracellular potassium.Methods
Adults aged≥18 years with an implantable cardioverter defibrillator (ICD) were randomized (1:1) to a control group or to an intervention that included guidance on potassium rich diets, potassium supplements, and MRA to increase p-K to target levels of 4.5-5.0 mmol/l for six months. Total-body-potassium (TBK) was measured by a Whole-Body-Counter along with p-K at baseline, after six weeks, and after six mont"],"journal":["PloS one"],"pubmed_title":["Treatment-induced increase in total body potassium in patients at high risk of ventricular arrhythmias; a randomized POTCAST substudy."],"pmcid":["PMC10355384"],"funding_grant_id":["NNF20OC0064048"],"pubmed_authors":["Frandsen E","Bundgaard H","Bosselmann H","Sakthivel T","Bruun N","Vinther M","Larroude C","Oturai P","Haugan K","Jensen HJ","Risum N","Zheng C","Saffi H","Jons C","Winslow U","Iversen K"],"additional_accession":[]},"is_claimable":false,"name":"Treatment-induced increase in total body potassium in patients at high risk of ventricular arrhythmias; a randomized POTCAST substudy.","description":"Objective
Hypokalemia is associated with increased risk of arrhythmias and it is recommended to monitor plasma potassium (p-K) regularly in at-risk patients with cardiovascular diseases. It is poorly understood if administration of potassium supplements and mineralocorticoid receptor antagonists (MRA) aimed at increasing p-K also increases intracellular potassium.Methods
Adults aged≥18 years with an implantable cardioverter defibrillator (ICD) were randomized (1:1) to a control group or to an intervention that included guidance on potassium rich diets, potassium supplements, and MRA to increase p-K to target levels of 4.5-5.0 mmol/l for six months. Total-body-potassium (TBK) was measured by a Whole-Body-Counter along with p-K at baseline, after six weeks, and after six mont","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2026-05-29T12:20:23.478Z","creation":"2025-02-19T03:57:02.289Z"},"accession":"S-EPMC10355384","cross_references":{"pubmed":["37467227"],"doi":["10.1371/journal.pone.0288756"]}}